Cashu
Congress reauthorizes Rare Pediatric Disease PRV program, preserving Atossa Therapeutics' DMD voucher eligibility
27 days ago
Stocks
Health Care
atos
Atossa Therapeutics
NASDAQ: ATOS
-0.15 (-3.21%)
4.53
USD
At close at Mar 06, 21:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
40.30M
Dividend Yield
0.00%
P/E Ratio
-1.34
EPS
-3.15
Revenue
-
Avg. Volume
93.83K
About
What does ATOS do?
Atossa Therapeutics, based in Seattle, focuses on developing oral (Z)-endoxifen for breast cancer treatment and prevention, having completed four Phase I and two Phase II clinical studies. The company went public on November 8, 2012, and employs 10 people.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.